GSK (LON:GSK) Earns “Buy” Rating from Jefferies Financial Group

GSK (LON:GSK)‘s stock had its “buy” rating reissued by analysts at Jefferies Financial Group in a report issued on Tuesday, Digital Look reports. They presently have a GBX 2,500 price objective on the stock. Jefferies Financial Group’s price objective would indicate a potential upside of 33.80% from the stock’s current price.

Other equities analysts have also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 2,000 target price on shares of GSK in a research note on Tuesday, September 29th. Berenberg Bank increased their price objective on shares of GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a report on Tuesday, September 15th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 1,975 price objective on shares of GSK in a research note on Tuesday, September 8th. Two equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of GBX 2,064.38.

GSK Stock Up 0.7%

LON GSK traded up GBX 13.50 during trading hours on Tuesday, reaching GBX 1,868.50. 5,106,011 shares of the company traded hands, compared to its average volume of 12,483,875. The stock has a market capitalization of £74.87 billion, a PE ratio of 15.86, a PEG ratio of 1.24 and a beta of 0.29. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. GSK has a 12 month low of GBX 1,592 and a 12 month high of GBX 2,282. The company has a 50 day moving average of GBX 1,845.67 and a two-hundred day moving average of GBX 1,924.07.

GSK (LON:GSK) last posted its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. As a group, equities analysts expect that GSK will post 175.98 earnings per share for the current year.

Insider Activity

In other news, insider Jonathan Symonds acquired 1,500 shares of GSK stock in a transaction dated Friday, September 18th. The stock was acquired at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal bought 637 shares of the stock in a transaction that occurred on Friday, September 18th. The stock was purchased at an average price of GBX 4,985 per share, for a total transaction of £31,754.45. Over the last 90 days, insiders have acquired 2,151 shares of company stock worth $6,021,921. Corporate insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.